Secreted PCSK9 decreases the number of LDL receptors in hepatocytes and in livers of parabiotic mice.

By Thomas A. Lagace, David E Curtis, R. Garuti, M. McNutt, Sahng Wook Park, Heidi B. Prather, Norma N. Anderson, Y. K. Ho, R. Hammer, Jay D. Horton. Journal of Clinical Investigation, 2006

715 citations recorded by the source corpus.

Subfields: Endocrinology, Diabetes and Metabolism, Surgery

View Paper: https://www.semanticscholar.org/paper/f9a52b17f02f2b34bc588674da8948559f181cb1

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Surgery

1. M. Manoharan
2. Robert Langer
3. Jay D. Horton
4. V. Mohanraj
5. Y. Chen

Citations in the corpus

• Therapeutic RNAi targeting PCSK9 acutely lowers plasma cholesterol in rodents and LDL cholesterol in nonhuman primates (2008, methodology): “Human PCSK9 protein concentration in collected mouse plasma was carried out by using a sandwich ELISA method as described (20, 23).”